Victory Capital Management Inc. Cuts Stock Holdings in Savara Inc (NASDAQ:SVRA)

Victory Capital Management Inc. reduced its stake in Savara Inc (NASDAQ:SVRA - Free Report) by 92.0% in the 4th quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 11,246 shares of the company's stock after selling 128,764 shares during the quarter. Victory Capital Management Inc.'s holdings in Savara were worth $35,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also modified their holdings of SVRA. Charles Schwab Investment Management Inc. grew its stake in shares of Savara by 5.7% in the 4th quarter. Charles Schwab Investment Management Inc. now owns 963,821 shares of the company's stock valued at $2,959,000 after buying an additional 52,204 shares during the period. Bank of New York Mellon Corp grew its position in Savara by 7.6% in the fourth quarter. Bank of New York Mellon Corp now owns 253,630 shares of the company's stock worth $779,000 after acquiring an additional 17,870 shares during the period. Rhumbline Advisers increased its stake in Savara by 6.8% during the fourth quarter. Rhumbline Advisers now owns 141,425 shares of the company's stock worth $434,000 after acquiring an additional 9,041 shares during the last quarter. China Universal Asset Management Co. Ltd. raised its position in Savara by 14.9% in the fourth quarter. China Universal Asset Management Co. Ltd. now owns 36,390 shares of the company's stock valued at $112,000 after purchasing an additional 4,732 shares during the period. Finally, SG Americas Securities LLC lifted its stake in shares of Savara by 14.0% in the 4th quarter. SG Americas Securities LLC now owns 51,589 shares of the company's stock valued at $158,000 after purchasing an additional 6,330 shares during the last quarter. 87.93% of the stock is owned by institutional investors and hedge funds.

Remove Ads

Savara Trading Up 3.0 %

SVRA traded up $0.08 during mid-day trading on Thursday, hitting $2.78. 1,107,031 shares of the stock were exchanged, compared to its average volume of 1,285,568. The firm's fifty day moving average is $2.72 and its two-hundred day moving average is $3.28. Savara Inc has a 1-year low of $2.26 and a 1-year high of $5.34. The company has a market cap of $477.10 million, a PE ratio of -6.47 and a beta of 0.60. The company has a current ratio of 17.70, a quick ratio of 17.70 and a debt-to-equity ratio of 0.13.

Analyst Upgrades and Downgrades

Several analysts recently issued reports on the stock. Wells Fargo & Company began coverage on shares of Savara in a report on Friday, December 20th. They issued an "overweight" rating and a $8.00 price objective on the stock. JMP Securities reiterated a "market outperform" rating and set a $9.00 price target on shares of Savara in a research report on Thursday, December 19th. One equities research analyst has rated the stock with a hold rating and five have issued a buy rating to the stock. According to MarketBeat, Savara has an average rating of "Moderate Buy" and an average price target of $8.83.

About Savara

Savara Inc, formerly Mast Therapeutics, Inc, is a clinical-stage pharmaceutical company. The Company is focused on the development and commercialization of novel therapies for the treatment of patients with rare respiratory diseases. Its pipeline includes AeroVanc, Molgradex and AIR001. AeroVanc is an inhaled formulation of vancomycin, which the Company is developing for the treatment of persistent methicillin-resistant Staphylococcus aureus, lung infection in cystic fibrosis patients.